Coqui RadioPharmaceuticals Corp. (Coqui Pharma) is relocating its proposed medical isotope Molybdenum 99 (Mo-99), which is used in approximately 18 million medical procedures each year in the U.S. Because of the critical medical need, the U.S. Government has identified establishing a commercial domestic source as a national priority and tasked the U.S. Department of Energy (DOE) with leading these efforts.

The DOE and Community Reuse Organization of East Tennessee (CROET) have granted a 170 acre site strategically located on Duct Island at the Heritage Center in Oak Ridge, formerly the K25 site, to Coqui Pharma. The relocation is an exciting development in the company's progress for a number of reasons, including the symbiotic relations with the surrounding community and the immense federal, local and state support of our mission. The land conveyance is just part of a generous incentive package from the DOE, CROET, State of Tennessee, Tennessee Valley Authority (TVA), the Roane Alliance and the City of Oak Ridge.

We are really excited about our new home at Oak Ridge. The new site is a huge development for our project and demonstrates the tremendous support we have received from the Federal Government, the State of Tennessee and the local nuclear community.

Oak Ridge has a long history with nuclear projects and we can take advantage of existing resources both at the site and in the surrounding community. The DOE providing this site also demonstrates its commitment to developing a domestic production source of these critical medical isotopes. We appreciate DOE's support for this effort.

Carmen Irene Bigles
President & CEO
www.coquipharma.com